Jasper Ridge Partners, L.P. Ngm Biopharmaceuticals Inc Transaction History

Jasper Ridge Partners, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $170,545 - $372,357	-284,242 Reduced 93.66%	19,250 $16,000
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $46,995 - $150,834	-44,758 Reduced 12.85%	303,492 $324,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $100,595 - $381,435	29,500 Added 9.25%	348,250 $1.75 Million
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $79,350 - $131,250	7,500 Added 2.41%	318,750 $4.09 Million
Q1 2022 May 13, 2022	BUY	$13.81 - $18.6 $13,810 - $18,600	1,000 Added 0.32%	311,250 $4.75 Million
Q2 2021 Aug 12, 2021	BUY	$15.06 - $30.03 $22,590 - $45,045	1,500 Added 0.49%	310,250 $6.12 Million
Q1 2020 May 13, 2020	BUY	$10.0 - $19.51 $17,500 - $34,142	1,750 Added 0.57%	308,750 $3.81 Million
Q4 2019 Feb 13, 2020	SELL	$9.97 - $20.28 $428,710 - $872,040	-43,000 Reduced 12.29%	307,000 $5.68 Million
Q3 2019 Nov 12, 2019	BUY	$13.09 - $18.19 $13,090 - $18,190	1,000 Added 0.29%	350,000 $4.85 Million
Q2 2019 Aug 09, 2019	BUY	$12.56 - $16.6 $4.38 Million - $5.79 Million	349,000 New	349,000 $5.11 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Jasper Ridge Partners, L.P., based on Form 13F filings with the SEC.

Stay updated on Jasper Ridge Partners, L.P. with notifications on news.